Before the listing on AktieTorget, Initiator Pharma carried out a preferential rights issue in the approx. amount of SEK 20.5 million. The rights issue was subscribed to approximately 44.1 million, representing a subscription rate of about 215 percent. The company will with the proceeds raised by the preferential rights issue, complete the preclinical development of the drug candidate IPED2015, a new treatment for erectile dysfunction and fill for a clinical phase I Trial.
For additional information about Initiator Pharma, please contact:
Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035
This information is the information that Initiator Pharma is required to disclose under the EU Market Abuse Regulation. The information was provided under the above contact person’s auspices, for publication on March 16th, 2017.
About Initiator Pharma
Initiator Pharma is a pharmaceutical company based in Aarhus, Denmark, established via a spin out from Saniona AB (listed on Nasdaq Stockholm First North Premier). The primary focus of the Company is the pharmaceutical candidate IPED2015, which constitutes a new treatment for the indication of erectile dysfunction (ED) – the inability of a man to achieve and maintain an erection and thus be able to complete sexual intercourse. Initiator Pharma’s new treatment method with IPED2015 is intended to treat the large group of patients suffering from erectile dysfunction who are resistant to current treatment methods.